MX336390B - Formulaciones fotosensibilizadoras mejoradas y su uso. - Google Patents

Formulaciones fotosensibilizadoras mejoradas y su uso.

Info

Publication number
MX336390B
MX336390B MX2012005452A MX2012005452A MX336390B MX 336390 B MX336390 B MX 336390B MX 2012005452 A MX2012005452 A MX 2012005452A MX 2012005452 A MX2012005452 A MX 2012005452A MX 336390 B MX336390 B MX 336390B
Authority
MX
Mexico
Prior art keywords
pdt
diseased tissue
photosensitizer
formulation
low concentration
Prior art date
Application number
MX2012005452A
Other languages
English (en)
Inventor
Volker Albrecht
Nikolay Nifantiev
Original Assignee
Biolitec Pharma Marketing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolitec Pharma Marketing Ltd filed Critical Biolitec Pharma Marketing Ltd
Publication of MX336390B publication Critical patent/MX336390B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación de baja concentración para fotosensibilizadores hidrofóbicos (PS) y un método mejorado para terapia fotodinámica ("PDT"). Se encontró que los tratamientos con PDT usando las formulaciones de baja concentración descritas, proporcionan una dosificación más exacta, más eficiente y más práctica. Se encontró que la formulación de la invención (1) reduce el tiempo para lograr una proporción suficiente de fotosensibilizador en el tejido enfermo contra el tejido sano. Como resultado, la formulación de la invención reduce el intervalo de tiempo entre la aplicación/administración de PS y la irradiación (el intervalo de luz medicinal o "DLI") y puede proporcionar una opción de tratamiento con PDT "en el mismo día". La formulación de la invención se puede usar para regímenes de tratamiento con PDT, en donde se administran fotosensibilizadores en al menos una dosis preseleccionada, incluyendo una terapia de baja concentración para PDT. En particular, cuando el meta tetra-hidroxi-fenil-clorin (m-THPC) es el fotosensibilizador, entonces una concentración de 0.8 mg/mL hasta 0.04 mg/mL en una mezcla de propilenglicol puro y etanol en una proporción de 3:2 por volumen, se acumula en el tejido enfermo y diferencia entre tejido enfermo y tejido normal de manera suficientemente rápida como para que sea posible una administración y activación de los procedimientos de tratamiento "de un día" o de un día para otro.
MX2012005452A 2004-08-16 2007-02-15 Formulaciones fotosensibilizadoras mejoradas y su uso. MX336390B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60226404P 2004-08-16 2004-08-16
US11/153,703 US7825153B2 (en) 2004-08-16 2005-06-15 Photosensitizer formulations and their use

Publications (1)

Publication Number Publication Date
MX336390B true MX336390B (es) 2016-01-18

Family

ID=35800792

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2007001902A MX2007001902A (es) 2004-08-16 2005-07-22 Formulaciones fotosensibilizadoras mejoradas y su uso.
MX2012005452A MX336390B (es) 2004-08-16 2007-02-15 Formulaciones fotosensibilizadoras mejoradas y su uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2007001902A MX2007001902A (es) 2004-08-16 2005-07-22 Formulaciones fotosensibilizadoras mejoradas y su uso.

Country Status (18)

Country Link
US (2) US7825153B2 (es)
EP (1) EP1786431B1 (es)
JP (1) JP5612246B2 (es)
KR (2) KR101074941B1 (es)
CN (1) CN101056642B (es)
AU (2) AU2005277790B2 (es)
BR (1) BRPI0514364B1 (es)
CA (1) CA2577441C (es)
DK (1) DK1786431T3 (es)
ES (1) ES2552033T3 (es)
HU (1) HUE026361T2 (es)
IL (1) IL181300A (es)
MX (2) MX2007001902A (es)
PL (1) PL1786431T3 (es)
PT (1) PT1786431E (es)
RU (1) RU2371181C2 (es)
SI (1) SI1786431T1 (es)
WO (1) WO2006023194A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10311027A1 (de) * 2003-03-13 2004-09-30 Siemens Ag Mess- und Simulationssystem für Werkzeug- oder Produktionsmaschinen
US20070031482A1 (en) * 2005-08-02 2007-02-08 Ceramoptec Industries, Ind. PDT treatment method for cellulites and cosmetic use
US20080275432A1 (en) * 2006-05-11 2008-11-06 Ceramoptec Industries, Inc. Photodynamic foam composition and sclerosis treatment
US8180444B2 (en) * 2007-06-22 2012-05-15 Biolitec Pharma Marketing Ltd Enhanced PhotoDynamic Therapy with immune system assist
US20100256125A1 (en) * 2009-04-06 2010-10-07 Zila Pharmaceuticals, Inc. Use of improved toluidine blue in photodynamic therapy
WO2010129775A1 (en) 2009-05-06 2010-11-11 University Of Virginia Patent Foundation Self-illuminated handheld lens for retinal examination and photography and related method thereof
RU2521327C1 (ru) * 2012-12-12 2014-06-27 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения Российской Федерации" (ФГБУ "МНИОИ им. П.А. Герцена" Минздрава России) Препарат для фотодинамической терапии и способ фотодинамической терапии рака с его использованием

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017501A (en) * 1975-10-24 1977-04-12 American Cyanamid Company Process for preparing pyridinium chloride salts of alkyl esters of 2-chloro-N-2-hydroxyethylacetamide
ZA855561B (en) * 1984-07-27 1986-03-26 Univ Illinois Photodynamic herbicides
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5162519A (en) * 1988-03-11 1992-11-10 Efamol Holdings Plc Porphyrins and cancer treatment
GB8805849D0 (en) 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
US4999375A (en) * 1989-04-11 1991-03-12 Hoffmann-La Roche Inc. Psoralen reagent compositions for extracorporeal treatment of blood
US5173504A (en) * 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
DK0552273T3 (da) * 1990-10-12 1996-12-30 Raychem Ltd Kredsløbsbeskyttelsesarrangement
US5492924A (en) * 1993-09-24 1996-02-20 Fox Chase Cancer Center Phorbine derivatives and their use in the diagnosis and therapy of cancer
US5576013A (en) * 1995-03-21 1996-11-19 Eastern Virginia Medical School Treating vascular and neoplastic tissues
US5616342A (en) * 1995-04-11 1997-04-01 Pdt, Inc. Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof
US5877165A (en) * 1995-11-02 1999-03-02 Brookhaven Science Associates Boronated porhyrins and methods for their use
US5895786A (en) * 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
AU750933B2 (en) * 1997-07-28 2002-08-01 Dermatolazer Technologies Ltd. Phototherapy based method for treating pathogens and composition for effecting same
US6609014B1 (en) * 1999-04-14 2003-08-19 Qlt Inc. Use of PDT to inhibit intimal hyperplasia
EP1262179A4 (en) * 2000-02-17 2004-06-23 Meiji Seika Kaisha PHOTODYNAMIC THERAPY FOR SELECTIVELY TREATING NEOVAISSEAUX IN THE BOTTOM OF THE EYE TISSUE
US6462192B2 (en) * 2001-01-23 2002-10-08 Miravant Pharmaceuticals, Inc. Processes for large scale production of tetrapyrroles
AU2002233092A1 (en) 2001-02-15 2002-08-28 Qlt Inc. Reduction or prevention of pdt related inflammation
EP1404334A4 (en) * 2001-05-15 2005-02-02 Faulk Pharmaceuticals Inc TARGETED ADMINISTRATION OF BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER
ATE336497T1 (de) * 2001-06-01 2006-09-15 Ceramoptec Gmbh Wasserlösliche porphyrinderivate für die photodynamische therapie, deren verwendung und herstellung
EP1277470A1 (fr) * 2001-07-17 2003-01-22 Steba Biotech N.V. Formulation galénique injectable pour utilisation dans un diagnostic ou une thérapie photodynamique et son procédé de préparation
EP1279676A1 (en) * 2001-07-19 2003-01-29 Institut Curie Porphyrin derivatives for photodynamic therapy
US7115617B2 (en) * 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
AU2002340676B2 (en) 2001-11-09 2008-12-11 Valeant Pharmaceuticals International, Inc. Compositions comprising a photosensitizer and a skin-penetration enhancer and their use in photodynamic treatment
US20030167033A1 (en) 2002-01-23 2003-09-04 James Chen Systems and methods for photodynamic therapy
US6949581B2 (en) * 2003-03-21 2005-09-27 Ceramoptec Industries, Inc. Water-soluble mono-PEGylated tetrapyrrole derivatives for photodynamic therapy and method of production

Also Published As

Publication number Publication date
RU2371181C2 (ru) 2009-10-27
JP2008509998A (ja) 2008-04-03
WO2006023194A2 (en) 2006-03-02
RU2007109602A (ru) 2008-09-27
KR20100040957A (ko) 2010-04-21
US20060035952A1 (en) 2006-02-16
IL181300A (en) 2016-04-21
CN101056642B (zh) 2011-08-17
CA2577441E (en) 2006-03-02
IL181300A0 (en) 2008-04-13
AU2009243407B2 (en) 2011-04-28
PT1786431E (pt) 2016-01-06
JP5612246B2 (ja) 2014-10-22
DK1786431T3 (en) 2016-01-25
PL1786431T3 (pl) 2016-04-29
HUE026361T2 (en) 2016-06-28
WO2006023194A3 (en) 2006-06-15
US7825153B2 (en) 2010-11-02
US20080195032A1 (en) 2008-08-14
BRPI0514364A (pt) 2008-06-10
ES2552033T3 (es) 2015-11-25
AU2005277790B2 (en) 2009-09-03
BRPI0514364B1 (pt) 2021-06-22
CA2577441A1 (en) 2006-03-02
KR101158192B1 (ko) 2012-06-20
MX2007001902A (es) 2007-04-25
EP1786431B1 (en) 2015-10-28
EP1786431A4 (en) 2012-06-13
AU2005277790A1 (en) 2006-03-02
US8580839B2 (en) 2013-11-12
SI1786431T1 (sl) 2016-01-29
KR101074941B1 (ko) 2011-10-18
KR20070048738A (ko) 2007-05-09
AU2009243407A1 (en) 2009-12-17
CN101056642A (zh) 2007-10-17
EP1786431A2 (en) 2007-05-23
CA2577441C (en) 2010-09-28

Similar Documents

Publication Publication Date Title
Dahlman et al. Laser photoradiation therapy of cancer
Pacifico et al. Photo (chemo) therapy for vitiligo
Calzavara-Pinton et al. A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 1: inflammatory and aesthetic indications
MX336390B (es) Formulaciones fotosensibilizadoras mejoradas y su uso.
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
WO2004064734A3 (en) Combination therapies for the treatment of cancer
Calzavara-Pinton et al. Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis
WO2005048955A3 (en) Preloading with macular pigment to improve photodynamic treament of retinal vascular disorders
Silva et al. Photodynamic therapy: dermatology and ophthalmology as main fields of current applications in clinic
Yang et al. Topical methotrexate pretreatment enhances the therapeutic effect of topical 5-aminolevulinic acid-mediated photodynamic therapy on hamster buccal pouch precancers
AU5574001A (en) Method for treatment of tumors using photodynamic therapy
AU2001236529A1 (en) Combination therapy for cancer
Brazzelli et al. Non-Invasive Evaluation of Tacalcitol Plus Puva versus Tacalcitol Plus UVB-NB in the Treatment of Psoriasis:“Right-Left Intra-Individual—Pre/Post Comparison Design”
Harvey et al. Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398
LOWE Optimizing therapy: tazarotene in combination with phototherapy
US8318794B2 (en) Method of use of porphyrins in preparing a medicament for sonodynamic therapy and a method of sonodynamic therapy using porphyrins
US20040110731A1 (en) Photodynamic therapy for the treatment of non-melanoma skin cancer
RU2313373C1 (ru) Способ лечения хронических заболеваний толстой кишки, протекающих с синдромом запора у детей
Satoskar et al. Management of oral leukoplakia with photodynamic therapy
CY1116935T1 (el) Βελτιωμενες συνθεσεις φωτοευαισθητοποιητη και η χρηση αυτων
Khurshid et al. Efficacy and safety of narrow band UVB in the treatment of chronic plaque psoriasis
HOUSEL et al. Photodynamic Therapy for Nonmelanoma Skin Cancer
He et al. Combination of vascular targeting PDT with combretastatin A4 phosphate
Tomio et al. Photoradiation therapy with hematoporphyrin as a selective technique for the treatment of malignant tumors
WO2020229878A1 (es) Composición de uso tópico para terapia fotodinámica